This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Corey and colleagues¹ reported that a recombinant glycoprotein vaccine failed to prevent genital herpes simplex virus 2 (HSV-2) infection. The study evaluated asymptomatic and symptomatic infections and symptomatic recurrences. None of these outcomes were modified by vaccine despite neutralizing and antibody titers that exceeded those produced during naturally acquired HSV-2 infection. The authors suggest that more information is needed about cellular and mucosal immune responses to HSV-2 infection before "we can attempt to identify laboratory-based correlates of immune protection." While more information would be helpful, the authors failed to consider currently available information that is relevant to the vaccine failure.

In recent years we have learned that viruses have evolved both offensive and defensive strategies. Viral proteins use cellular receptors for entry and manipulate cell death signals as part of their offensive strategies, while they encode proteins to counteract host immunity as part of their defense. . . . [Full Text of this Article]